Approved Drugs for Immunology/Infectious Diseases
Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals;
For the treatment of itching associated with allergic conjunctivitis, Approved September 2009
Berinert (C1 Esterase Inhibitor (Human)); CSL Behring;
For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009
Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb;
For the treatment of bacterial conjunctivitis, Approved June 2009
Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009
Coartem (artemether/lumefantrine); Novartis;
For the treatment of malaria infections due to Plasmodium falciparum, Approved April 2009
Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline;
For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009
Ilaris (canakinumab); Novartis;
For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved June 2009
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Intercell AG;
For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009
Vibativ (telavancin); Theravance;
For the treatment of complicated skin and skin structure infections, Approved September 2009
Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics;
For the treatment of acute herpetic keratitis, Approved September 2009
Aptivus (tipranavir); Boehringer Ingelheim;
For the treatment of HIV, Approved June 2008
Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals;
For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008
Cinryze (C1 Inhibitor (Human)); Lev Pharmaceuticals;
For the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema, Approved October 2008
Intelence (etravirine); Tibotec;
For the treatment of HIV-1, Approved January 2008
Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals;
For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008
Rotarix (Rotavirus Vaccine, Live, Oral); GlaxoSmithKline;
For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics, Approved April 2008
Tysabri (natalizumab); Biogen IDEC;
For the maintenance treatment of moderate to severe Crohn’s disease, Approved January 2008
Viread (tenofovir disoproxil fumarate); Gilead;
For the treatment of hepatitis B, Approved August 2008
Altabax (retapamulin); GlaxoSmithKline;
For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007
AzaSite (azithromycin); InSite Vision;
For the treatment of bacterial conjunctivitis, Approved April 2007
Doribax (doripenem); Johnson & Johnson;
For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007
Extina (ketoconazole); Stiefel;
For the treatment of seborrheic dermatitis, Approved June 2007
Isentress (raltegravir); Merck;
For the treatment of HIV-1, Approved October 2007
Selzentry (maraviroc); Pfizer;
For the treatment of CCR5-tropic HIV-1, Approved August 2007
Veramyst (fluticasone furoate); GlaxoSmithKline;
For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007
Xyzal (levocetirizine dihydrochloride); UCB;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Eraxis (anidulafungin); Pfizer;
For the treatment of Candida fungal infections, Approved February 2006
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck;
For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006
Noxafil (posaconazole); Schering-Plough;
For the treatment of fungal infections, Approved in September 2006
Prezista (darunavir); Tibotec;
For the treatment of treatment-resistant HIV infections, Approved June 2006
Rotateq (rotavirus vaccine, live oral pentavalent); Merck;
For the prevention of gastroenteritis associated with rotavirus infections in infants, Approved February 2006
Tyzeka (telbivudine); Idenix Pharma;
For the treatment of hepatitis B virus, Approved October 2006
Veregen (kunecatechins); Medigene;
For the treatment of external genital and perianal warts, Approved October 2006
Aptivus (tipranavir); Boehringer Ingelheim;
For the adjunctive treatment of HIV-1 infections, Approved June, 2005
Baraclude (entecavir); Bristol-Myers Squibb;
For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005
Tygacil (tigecycline); Wyeth;
For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005
Ketek (telithromycin); Sanofi-aventis;
For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia., Approved April 2004
Tindamax, tinidazole; Presutti Laboratories;
For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis, Approved May, 2004
Xifaxan (rifaximin); Salix Pharmaceuticals;
For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli, Approved May 2004
Amevive (alefacept); Biogen IDEC;
For moderate to severe chronic plaque psoriasis., Approved January 2003
FluMist ( Influenza Virus Vaccine); MedImmune;
For the prevention of disease caused by influenza A and B viruses, Approved June 2003
Fuzeon (enfuvirtide); Trimeris, Roche;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003
Lexiva (fosamprenavir calcium); GlaxoSmithKline;
For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003
Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003
Alinia (nitazoxanide); Romark Laboratories;
For the treatment Diarrhea caused by Cryptosporidium and Giardia in children., December 2002
Clarinex; Schering-Plough;
Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002
Daptacel; Sanofi Pasteur;
Pediatric vaccine for immunization against diptheria, tetanus and pertussis, Approved May 2002
Fluzone Preservative-free; Sanofi Pasteur;
Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002
Hepsera (adefovir dipivoxil); Gilead;
For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002
Pediarix Vaccine; GlaxoSmithKline;
For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old., Approved December 2002
Pegasys (peginterferon alfa-2a); Roche;
For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002
Restasis (cyclosporine ophthalmic emulsion); Allergan;
For the treatment of low tear production., December 2002
Sustiva; Bristol-Myers Squibb;
Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002
Vfend (voriconazole); Pfizer;
For the treatment of fungal infections, Approved May 2002
Avelox I.V. (moxifloxacin hydrochloride); Bayer;
Injectable antibacterial agent for adults with susceptible strains of bacterial infections, Approved November 2001
Cancidas; Merck;
Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001
Peg-Intron (peginterferon alfa-2b); Schering-Plough;
For the treatment of chronic hepatitis C, Approved January 2001
Rebetol (ribavirin); Schering-Plough;
For the treatment of chronic hepatitis C, Approved July 2001
Spectracef; TAP Pharmaceuticals;
Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001
Twinrix; GlaxoSmithKline;
For the prevention of hepatitis A and B, Approved May 2001
Valcyte (valganciclovir HCl); Roche;
For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001
Viread (tenofovir disoproxil fumarate); Gilead;
Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001
Xigris (drotrecogin alfa [activated]); Eli Lilly;
For the treatment of severe sepsis, Approved November 2001
ABREVA (docosanol); AVANIR PHARMACEUTICALS;
Cold sore/fever blister, Approved July 2000
Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories;
For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000
Cefazolin and Dextrose USP; B Braun Medical;
Respiratory tract infections, Approved July 2000
Children's Motrin Cold; McNeil Consumer Products;
For temporary relief of the common cold, Approved August 2000
Evoxac; SnowBrand Pharmaceuticals;
For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome, Approved January 2000
Kaletra Capsules and Oral Solution; Abbott Laboratories;
For the treatment of HIV-1 infection, Approved September 2000
Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000
Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough;
For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000
Malarone (atovaquone; proguanil hydrochloride) Tablet; GlaxoSmithKline;
For the treatment and prevention of Plasmodium falciparum malaria, Approved July 2000
Rapamune (sirolimus) Tablets; Wyeth;
For treatment of kidney rejection, Approved August 2000
Rid Mousse; Soltec Research;
For the treatment of head, pubic (crab), and body lice, Approved March 2000
Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000
Trivagizole 3 (clotrimazole) Vaginal Cream; Taro Pharmaceuticals;
For the treatment of vaginal yeast infections, Approved April 2000
Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline;
For the treatment of HIV-1 infection, Approved November 2000
Agenerase (amprenavir); GlaxoSmithKline;
For the treatment of HIV-1 infection., Approved April 1999
Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
Treatment for bacterial vaginosis, Approved August 1999
Famvir (famciclovir); SmithKline Beecham;
Treatment for Herpes Simplex Infections in HIV-infected patients, Approved January 1999
Norvir (ritonavir); Abbott Laboratories;
Treatment for HIV infection, Approved June 1999
Panretin Gel; Ligand Pharmaceuticals;
Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma., Approved June 1999
Rapamune (sirolimus) oral solution; Wyeth;
Oral solution of sirolimus, Approved September 1999
Relenza; GlaxoSmithKline;
Treatment for uncomplicated acute illness due to influenza virus, Approved July 1999
Synercid I.V.; Rhone Poulenc Rorer;
quinupristin and dalfopristin for injection, Approved September 1999
Tamiflu capsule; Roche;
Oseltamivir phosphate capsule, October 27, 1999
Vistide (cidofovir); Gilead;
For the treatment of cytomegalovirus (CMV) retinitis, Approved March 1999
Allegra-D; Hoechst Marion Roussel;
Treatment for nasal congestion due to seasonal allergy, Approved March 1998
CellCept; Roche;
Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998
Clemastine fumarate syrup; Morton Grove Pharmaceuticals;
Generic equivalent of Tavist Syrup, Approved March 1998
Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
Treatment for bacterial vaginosis, Approved March 1998
Dynabac; Sanofi-aventis;
Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998
REBETRON (TM) Combination Therapy; Schering-Plough;
Treatment for Chronic Hepatitis C, Approved June 1998
Simulect; Novartis;
Treatment for acute organ transplant rejection, Approved May 1998
Timentin; SmithKline Beecham;
Treatment for wide range of infections in children, Approved January 1998
Viroptic; King Pharmaceuticals;
Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998
INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham;
Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997
Acyclovir Capsules; Teva Pharmaceutical;
Generic equivalent of Zovirax, Approved April 1997
Aldara (imiquimod); 3M Pharmaceuticals;
Treatment for external genital and perianal warts, Approved March 1997
Aphthasol; Block Drug Company;
Treatment for canker sores, Approved December 1997
Combivir; GlaxoSmithKline;
Treatment for AIDS and HIV Infection, Approved September 1997
Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals;
Treatment for external genital and perianal warts, Approved March 1997
Famvir (famciclovir); SmithKline Beecham;
Treatment for genital herpes, Approved September 17, 1997
Flagyl ER; Searle;
Treatment for bacterial vaginosis, Approved December 1997
Flonase Nasal Spray; GlaxoSmithKline;
Treatment for seasonal and perennial allergic rhinitis, Approved November 1997
Fortovase; Roche;
Treatment for HIV infection, Approved November 1997
INFERGEN (interferon alfacon-1); Amgen;
Treatment for chronic hepatitis C virus, Approved October 1997
Intron A (interferon alfa-2b, recombinant); Schering-Plough;
Treatment for hepatitis C, Approved March 1997
Norvir (ritonavir); Abbott Laboratories;
Treatment for HIV infection, Approved March 1996/March 1997
Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn;
Treatment for HIV-1 infection, Approved April 1997
SPORANOX (itraconazole); Janssen Pharmaceutica;
Treatment for oral thrush, Approved March 1997
Stromectol (ivermectin); Merck;
Treatment for nondisseminated intestinal threadworm, Approved March 1997
Taxol; Bristol-Myers Squibb;
Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997
Trovan; Pfizer;
Treatment for bacterial infections, Approved December 1997
VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals;
Treatment for HIV infection in adults and children, Approved March 1997
Zerit (stavudine); Bristol-Myers Squibb;
Treatment for infants and children infected with HIV, Approved January 1997
Albenza (albendazole); SmithKline Beecham;
Treatment for parasitic infections caused by worms, Approved June 1996
Apthasol (Amlexanox); Access Pharmaceuticals;
Treatment for canker sores, Approved May 1996
Carrington patch; Carrington Laboratories;
Treatment for canker sores, Approved May 1996
Confide; Johnson & Johnson;
HIV testing and counseling service, Approved May 1996
Crixivan (Indinavir sulfate); Merck;
Treatment for HIV infection, Approved March 1996
Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer;
Treatment for mastocytosis, Approved April 1996
Havrix; SmithKline Beecham;
Treatment for hepatitis A, Approved March 1996
Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals;
Treatment for nail fungal infections, Approved May 1996
Leukine (sargramostim); Immunex;
Treatment for the replenishment of white blood cells, Approved November 1996
Oral Cytovene; Roche;
Treatment for the prevention of cytomegalovirus (CMV), Approved December 1996
RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996
Videx (didanosine); Bristol-Myers Squibb;
Treatment of HIV infection, Approved June 1996
Viramune (nevirapine); Boehringer Ingelheim;
Treatment for HIV infection, Approved June 1996
Vistide (cidofovir); Gilead;
Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996
Vitrasert Implant; Chiron;
Drug delivery system for the treatment of cytomegalovirus, Approved March 1996
Zithromax (azithromycin); Pfizer;
Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996
Cedax (ceftibuten); Schering-Plough;
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995
Clarithromycin (Biaxin); Abbott Laboratories;
Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995
Epivir (lamivudine); GlaxoSmithKline;
Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995
Intron A (Interferon alfa-2b, recombinant); Schering-Plough;
An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995
Invirase (saquinavir); Roche;
Treatment for HIV/AIDS, Approved on December 7, 1995
Valtrex (valacyclovir HCl); GlaxoSmithKline;
Treatment for recurrent genital herpes, Approved December 1995
Western blot confirmatory device; Epitope;
Confirmatory test for HIV, Approved in December 1995
Zerit (stavudine); Bristol-Myers Squibb;
Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995
Zyrtec (cetirizine HCl); Pfizer;
Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995
